Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

To install click the Add extension button. That's it.

The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.

4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
Live Statistics
English Articles
Improved in 24 Hours
Added in 24 Hours
Languages
Recent
Show all languages
What we do. Every page goes through several hundred of perfecting techniques; in live mode. Quite the same Wikipedia. Just better.
.
Leo
Newton
Brights
Milds

From Wikipedia, the free encyclopedia

KLS-13019
Identifiers
  • 1-[3-[[3,5-dihydroxy-4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]phenyl]methyl]azetidin-1-yl]ethanone
CAS Number
PubChem CID
Chemical and physical data
FormulaC22H29NO3
Molar mass355.478 g·mol−1
3D model (JSmol)
  • CCCCCC1=CC(=C(C(=C1F)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
  • InChI=1S/C22H29NO3/c1-13(2)18-6-5-14(3)7-19(18)22-20(25)9-16(10-21(22)26)8-17-11-23(12-17)15(4)24/h7,9-10,17-19,25-26H,1,5-6,8,11-12H2,2-4H3/t18-,19+/m0/s1
  • Key:VWVIOABMCXYUAS-RBUKOAKNSA-N

KLS-13019 is a cannabidiol derivative that has been modified on the side chain to improve solubility and tissue penetration properties. It was developed and patented by Neuropathix subsidiary Kannalife and found to be 50x more potent than cannabidiol as a neuroprotective agent, thought to be mediated by modulation of the sodium-calcium exchanger channel. It also had a higher therapeutic index than cannabidiol.[1][2][3] Both KLS-13019 and cannabidiol, prevented the development of CIPN, while only KLS-13019 uniquely reversed neuropathic pain from chemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[4]

See also

References

  1. ^ Kinney WA, McDonnell ME, Zhong HM, Liu C, Yang L, Ling W, et al. (April 2016). "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Medicinal Chemistry Letters. 7 (4): 424–8. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656. PMID 27096053.
  2. ^ Brenneman DE, Petkanas D, Kinney WA (September 2018). "Pharmacological Comparisons Between Cannabidiol and KLS-13019". Journal of Molecular Neuroscience. 66 (1): 121–134. doi:10.1007/s12031-018-1154-7. PMC 6150782. PMID 30109468.
  3. ^ Brenneman DE, Kinney WA, Ward SJ (August 2019). "Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity". Journal of Molecular Neuroscience. 68 (4): 603–619. doi:10.1007/s12031-019-01321-z. PMC 6615992. PMID 31077084.
  4. ^ Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ (April 2021). "Behavioral and pharmacological effects of cannabidiol (CBD) and the CBD analogue KLS‐13019 in mouse models of pain and reinforcement". British Journal of Pharmacology. 178 (15): 3067–3078. doi:10.1111/bph.15486. PMID 33822373. S2CID 233035597.
This page was last edited on 14 August 2023, at 13:56
Basis of this page is in Wikipedia. Text is available under the CC BY-SA 3.0 Unported License. Non-text media are available under their specified licenses. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. WIKI 2 is an independent company and has no affiliation with Wikimedia Foundation.